Key result
Review summarizes revised hemodynamic definitions, diagnostic algorithms, and emerging therapies for pulmonary hypertension.
Why the study?
Significant progress has occurred in pulmonary hypertension, including a revised hemodynamic definition, updated diagnostic algorithms, and emerging therapies alongside established treatment pathways.
This review summarizes the current diagnostic algorithms, revised hemodynamic definitions, and established and novel treatment pathways for pulmonary hypertension.
Supports revised PH hemodynamic criteria and pathways now; leaves open validation of novel therapies in trials.
Over the last decades, significant progress has been achieved in the pulmonary hypertension (PH) field. Pathophysiology of PH has been studied, leading to the classification of PH patients into five groups, while the hemodynamic definition has been recently revised. A diagnostic algorithm has been established and awareness has been raised in order to minimize diagnosis delay. The pulmonary arterial hypertension (PAH) treatment strategy includes the established three pathways of endothelin, nitric oxide-phosphodiesterase inhibitor, and prostacyclin pathway, but new therapeutic options are now being tested. The aim of this review is to summarize the existing practice and to highlight the novelties in the field of PH.
No takes yet. Share an insight, caveat, or question.
Ntiloudi et al. (2024) conducted a review in Pulmonary Hypertension. This review summarizes the revised hemodynamic definition, diagnostic algorithm, and established treatment pathways for pulmonary hypertension, highlighting new therapeutic options under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: